688221 前沿生物
2025/06 - 中期2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)-8.910-16.214-21.828-20.377-13.090
总资产报酬率 ROA (%)-5.602-10.191-14.457-14.434-10.301
投入资产回报率 ROIC (%)-6.050-11.013-15.867-15.742-11.050

边际利润分析
销售毛利率 (%)30.98933.92728.99518.605-30.438
营业利润率 (%)-165.670-155.317-286.857-421.616-660.429
息税前利润/营业总收入 (%)-167.538-149.998-281.255-421.061-667.212
净利润/营业总收入 (%)-166.018-155.540-287.935-421.008-654.939

收益指标分析
经营活动净收益/利润总额(%)103.264137.158106.828111.148119.975
价值变动净收益/利润总额(%)2.218-41.799-5.065-5.590-14.330
营业外收支净额/利润总额(%)0.2100.1440.374-0.144-0.838

偿债能力分析
流动比率 (X)2.8823.0942.9015.0723.949
速动比率 (X)2.7162.9902.7464.8713.852
资产负债率 (%)37.23237.01937.26230.67027.734
带息债务/全部投入资本 (%)18.99820.97214.0507.5879.575
股东权益/带息债务 (%)360.212321.530486.4361,009.651813.142
股东权益/负债合计 (%)168.586170.135168.373226.052260.565
利息保障倍数 (X)110.251-27.062-42.1077,917.32554.367

营运能力分析
应收账款周转天数 (天)122.604135.910156.202124.219240.922
存货周转天数 (天)229.331210.543254.308245.900177.669